UA55763A - Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе - Google Patents
Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе Download PDFInfo
- Publication number
- UA55763A UA55763A UA2002064689A UA200264689A UA55763A UA 55763 A UA55763 A UA 55763A UA 2002064689 A UA2002064689 A UA 2002064689A UA 200264689 A UA200264689 A UA 200264689A UA 55763 A UA55763 A UA 55763A
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- nebulizer
- bronchial asthma
- ambrobene
- optimization
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 14
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000005457 optimization Methods 0.000 title abstract 2
- 239000006199 nebulizer Substances 0.000 claims abstract description 18
- LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 229940124630 bronchodilator Drugs 0.000 claims abstract description 7
- 230000001813 broncholytic effect Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 11
- 230000005713 exacerbation Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 229960004436 budesonide Drugs 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 230000000510 mucolytic effect Effects 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 9
- 206010036790 Productive cough Diseases 0.000 description 7
- 208000024794 sputum Diseases 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000002664 inhalation therapy Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000037874 Asthma exacerbation Diseases 0.000 description 2
- 206010006440 Bronchial obstruction Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 241000288140 Gruiformes Species 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229960001037 fenoterol hydrobromide Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе предусматривает применение бронхолитических, муколитических и глюкокортикостероидных препаратов. С помощью небулайзера больным с перерывами вводят раствор беродуала в разведении с физиологическим раствором. Затем вводят раствор амбробене в разведении с физиологическим раствором, а через час – будесонид в дозирующем аэрозольном ингаляторе.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002064689A UA55763A (ru) | 2002-06-07 | 2002-06-07 | Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002064689A UA55763A (ru) | 2002-06-07 | 2002-06-07 | Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA55763A true UA55763A (ru) | 2003-04-15 |
Family
ID=74207123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002064689A UA55763A (ru) | 2002-06-07 | 2002-06-07 | Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA55763A (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020031148A1 (en) | 2018-08-10 | 2020-02-13 | Tykhonivska Nataliya | Pharmaceutical composition, medicinal product and method of treatment of bronchopulmonary obstructive diseases |
-
2002
- 2002-06-07 UA UA2002064689A patent/UA55763A/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020031148A1 (en) | 2018-08-10 | 2020-02-13 | Tykhonivska Nataliya | Pharmaceutical composition, medicinal product and method of treatment of bronchopulmonary obstructive diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2769397C2 (ru) | Композиции и способы лечения передозировки опиоидами | |
| Schuh et al. | Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma | |
| Derom et al. | Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. | |
| Nichol et al. | Prostaglandin F2 alpha enhancement of capsaicin induced cough in man: modulation by beta 2 adrenergic and anticholinergic drugs. | |
| Berry et al. | Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD | |
| Dudgeon | Dyspnea, death rattle, and cough | |
| JP2016521680A (ja) | 経鼻投与 | |
| Pierce et al. | A comparative study of atropine methonitrate, salbutamol, and their combination in airways obstruction. | |
| Tønnesen et al. | Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction | |
| Mohideen et al. | Basics of Management of Medical Emergencies in Dental Offi ce and Emergency Drug Kit | |
| Kunkel et al. | Respimat®(a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients | |
| Barry et al. | Nebuliser therapy in childhood | |
| MORIKAWA et al. | Actions of moguisteine on cough and pulmonary rapidly adapting receptor activity in the guinea pig | |
| JP2003535130A (ja) | ジメチルスルホンの経口投与によるいびきの管理 | |
| Wilcock et al. | Safety and efficacy of nebulized lignocaine in patients with cancer and breathlessness | |
| Gervais et al. | Bronchodilatation with a metered-dose inhaler plus an extension, using tidal breathing vs jet nebulization | |
| O′ Connell et al. | Effect of clonidine on induced cough and bronchoconstriction in guinea pigs and healthy humans | |
| BR122023024228A2 (pt) | Usos de uma composição compreendendo nalbufina para o tratamento de falta de ar e dispneia | |
| UA55763A (ru) | Способ оптимизации лечения обострений бронхиальной астмы на стационарном этапе | |
| Stauder et al. | Terbutaline Aerosol from a Metered Dose Inhaler with a 750-ml Spacer or as a Nebulized Solution: Comparison of Two Delivery Systems for Bronchodilator Aerosol | |
| Cohen | Clinical and physiologic “significance” of drug-induced changes in nasal flow/resistance | |
| Watanabe et al. | Bronchodilator effects of nebulized fenoterol: a comparison with isoproterenol | |
| Pallares et al. | A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma | |
| Boyan et al. | The electroencephalographic pattern during steroid narcosis. | |
| JP2013511528A (ja) | 喘息の急性憎悪の治療及びそれに罹患した患者の入院の可能性の低減 |